Immatics Biotechnologies GmbH-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013209
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA300/301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of its drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Immatics Biotech Raises USD58 Million in Series E Financing 10
immatics biotech Raises Additional USD29.8 Million in Second Tranche of Series D Financing 11
Partnerships 12
MorphoSys Enters into Agreement with Immatics Biotech 12
immatics Enters Into R&D Agreement With Roche For Cancer Vaccine 13
Licensing Agreements 15
Amgen Enters into Licensing Agreement with Immatics Biotech 15
Immatics Biotech Enters into Licensing Agreement with Sanquin Blood Supply Foundation 16
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 17
Equity Offering 18
Immatics US Raises USD10 Million in Financing 18
Immatics Biotechnologies GmbH – Key Competitors 19
Immatics Biotechnologies GmbH – Key Employees 20
Immatics Biotechnologies GmbH – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Joint Venture 21
Recent Developments 22
Corporate Communications 22
Jan 08, 2016: Immatics Appoints Katina Dorton as Chief Financial Officer 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Immatics Biotechnologies GmbH, Deals By Therapy Area, 2011 to YTD 2017 8
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Immatics Biotech Raises USD58 Million in Series E Financing 10
immatics biotech Raises Additional USD29.8 Million in Second Tranche of Series D Financing 11
MorphoSys Enters into Agreement with Immatics Biotech 12
immatics Enters Into R&D Agreement With Roche For Cancer Vaccine 13
Amgen Enters into Licensing Agreement with Immatics Biotech 15
Immatics Biotech Enters into Licensing Agreement with Sanquin Blood Supply Foundation 16
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 17
Immatics US Raises USD10 Million in Financing 18
Immatics Biotechnologies GmbH, Key Competitors 19
Immatics Biotechnologies GmbH, Key Employees 20
Immatics Biotechnologies GmbH, Other Locations 21
Immatics Biotechnologies GmbH, Joint Venture 21

★海外企業調査レポート[Immatics Biotechnologies GmbH-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Miracor Medical Systems GmbH:製品パイプライン分析
    Summary Miracor Medical Systems GmbH (Miracor Medical) is a medical device company that develops and commercializes pressure-controlled intermittent coronary sinus occlusions. The company offers products for continuous monitoring of coronary sinus pressure dynamics. It offers impulse console and imp …
  • Sectra AB (SECT B):企業の財務・戦略的SWOT分析
    Sectra AB (SECT B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Baxter International Inc (BAX):企業の財務・戦略的SWOT分析
    Baxter International Inc (BAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • High Peak Royalties Ltd (HPR):電力:M&Aディール及び事業提携情報
    Summary High Peak Royalties Limited (High Peak) is a leading utility company that builds a portfolio of diversified resource royalties with projects in exploration, pre-production and producing phases. It assesses a regular flow of potential royalty investments across the resources sector. The compa …
  • Foamix Pharmaceuticals Ltd (FOMX):企業の財務・戦略的SWOT分析
    Summary Foamix Pharmaceuticals Ltd (Foamix), formerly Foamix Ltd is a pharmaceutical company that develops and commercializes proprietary topical drugs for various dermatological therapies. The company’s product candidates include FMX101, a minocycline foam which is intended for the treatment of mod …
  • Vornado Realty Trust:企業の戦略・SWOT・財務情報
    Vornado Realty Trust - Strategy, SWOT and Corporate Finance Report Summary Vornado Realty Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • New York Power Authority:発電所・企業SWOT分析
    New York Power Authority - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Biogen, Inc.:戦略・SWOT・企業財務分析
    Biogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Biogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Warner Media LLC.:企業の戦略・SWOT・財務分析
    Warner Media LLC. - Strategy, SWOT and Corporate Finance Report Summary Warner Media LLC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Dart Group PLC:企業の戦略・SWOT・財務情報
    Dart Group PLC - Strategy, SWOT and Corporate Finance Report Summary Dart Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • ResCare Inc:企業の戦略的SWOT分析
    ResCare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Gilead Sciences Inc (GILD)-医療機器分野:企業M&A・提携分析
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) in …
  • BFS Group Ltd:企業の戦略・SWOT・財務分析
    BFS Group Ltd - Strategy, SWOT and Corporate Finance Report Summary BFS Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Australia and New Zealand Banking Group Ltd:戦略・SWOT・企業財務分析
    Australia and New Zealand Banking Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Australia and New Zealand Banking Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Power Assets Holdings Limited:企業の戦略・SWOT・財務情報
    Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • EyePoint Pharmaceuticals Inc (PSDV):企業の財務・戦略的SWOT分析
    Summary EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. EyePoint dura …
  • Allot Communications Ltd. (ALLT):企業の財務・戦略的SWOT分析
    Allot Communications Ltd. (ALLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Swissquote Group Holding Ltd (SQN):企業の財務・戦略的SWOT分析
    Swissquote Group Holding Ltd (SQN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Prysmian S.p.A.:企業のM&A・事業提携・投資動向
    Prysmian S.p.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prysmian S.p.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Liberty Media Corp (LSTZA):企業の財務・戦略的SWOT分析
    Liberty Media Corp (LSTZA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆